Chemotherapy News and Research

Latest Chemotherapy News and Research

Cannabis-based medications prove effective in relieving pain

Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.

7 Aug 2012

Viewpoints: Mass. at disadvantage in cutting health costs; McDonnell says Va. can point to better way

Massachusetts will be the first state to try to cap overall health care spending, both private and public, so that it will grow no faster than the state economy. The state was able to reach near-universal coverage because the vast majority of its population was already covered by some form of insurance. It also could subsidize coverage for the uninsured using a big pool of money that had been used for charity care. But when it comes to controlling health care costs, Massachusetts has no advantage, and in fact is starting behind most other states.

7 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Scientists identify key factor that drives resistance to cancer drug

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.

6 Aug 2012

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

6 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

Allergies may reduce risk of brain cancer

New research adds to the growing body of evidence suggesting that there's a link between allergies and reduced risk of a serious type of cancer that starts in the brain. This study suggests the reduced risk is stronger among women than men, although men with certain allergy profiles also have a lower tumor risk.

3 Aug 2012

Longer looks: Mississippi learns from Iran's health care system

Sabrina Seeling seemed too young to die. ... One night she stayed up all night translating a Latin text into English for a college paper. ... During the all-nighter, Ms. Seelig took Ephedra, a stimulant diet drug that had been banned by the Food and Drug Administration three years earlier, and had a few beers. ... When she felt sick, she called Poison Control for help, and spoke very clearly, a recording of the call shows.

3 Aug 2012

Mammography oversold by breast cancer charity

The world’s largest breast cancer charity comes under fire from experts today for using misleading statistics to persuade women to undergo mammography.

3 Aug 2012

Combination hormonal therapy improves survival in advanced breast cancer

A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.

2 Aug 2012

MLK3 protein critical driver of breast cancer cell migration and invasion

By identifying a key protein that tells certain breast cancer cells when and how to move, researchers at Michigan State University hope to better understand the process by which breast cancer spreads, or metastasizes.

2 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Chk1 gene alone is sufficient to kill cancer cells

Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.

1 Aug 2012

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

31 Jul 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

GenomePooling™ method is sensitive and accurate

31 Jul 2012

Viewpoints: Health law no threat to innovation; Failure to expand Medicaid would 'doom' thousands; Don't stigmatize mentally ill

For better or worse, the Democrats incorporated a good deal of mainstream Republican thinking about health care reform from the past decade, including mandated coverage and health insurance exchanges, into the Affordable Care Act. This leaves the GOP, embarrassingly, with little to say about what is wrong with the act.

31 Jul 2012

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.

30 Jul 2012

Antioxidants and pancreatic cancer risk: an interview with Dr Andrew Hart

The antioxidants that we mainly looked at were selenium, vitamin C and vitamin E. They are chemicals which inactivate pro-oxidants or free radicals. Smoking and normal metabolism can lead to the production of free radicals.

30 Jul 2012